NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kayothera

Kayothera

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://kayothera.com/

Last Round

Grant

Jul 19, 2023

Total Funding Raised

$13.2M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Kayothera is a biotechnology company that develops first-in-class, oral, small-molecule inhibitors of the retinoid nuclear receptor pathway for the treatment of cancer and cardiometabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

drug discoverysmall-molecule inhibitorsbiotechnologyoncology therapeuticscardiometabolic diseasepreclinical developmentnuclear receptor pathwaysbiotech startupsmall business innovation researchSBIRdrug pipelinetherapeutic candidateind-enabling studiesfirst-in-class drugs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kayothera Comparables

Compare Kayothera with similar companies based on industry and business-model similarity.

Kayothera comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Io Therapeutics, Inc.
82%
Orphagen Pharmaceuticals
82%
Forkhead Biotherapeutics, Inc.
73%

Kayothera Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 19, 2023
Series A ExtensionJul 19, 2023
Series AMar 16, 2022
SeedAug 12, 2019
SeedMar 28, 2018

Key People

Founding team and executive leadership

Merika Koday

Chief Operating Officer, Board Member

Executive Team

Kayothera Investors

Notable investors and investment history

Kayothera investors
InvestorRounds
Accelerator Life Science PartnersSeries A, Series A Extension
Foundation Venture Capital GroupSeed
New Jersey Health FoundationSeed
NIH RADxSeries A Extension, Grant
WRF CapitalSeries A Extension
Washington Research Foundation CapitalSeries A Extension
Pier 70 VenturesSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Monthly visitors increased 108% MoM, reaching 1.7K.

  • Jul 19, 2023

    Received funding from Andy Hill Cancer Research Endowment Fund and NIH RADx.

Kayothera Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kayothera Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kayothera's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range6
Year Founded2019
Last FundingJul 19, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.